Chronic aryl hydrocarbon receptor activation and skeletal myopathy in chronic kidney disease
慢性肾病中的慢性芳烃受体激活和骨骼肌病
基本信息
- 批准号:10670948
- 负责人:
- 金额:$ 3.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-16 至 2024-05-07
- 项目状态:已结题
- 来源:
- 关键词:ACTA1 geneAblationAcetic AcidsAffectAmericanAnabolismAnimal ModelAreaAryl Hydrocarbon ReceptorAtrophicAutomobile DrivingAutophagocytosisBinding ProteinsBioenergeticsBiologyCachexiaCalpainCaspaseCatabolismChronicChronic Kidney FailureCre lox recombination systemCytochrome P450DataDependovirusDevelopmentDialysis procedureDrug Metabolic DetoxicationEnzymesFatigueFellowshipFoundationsFunctional disorderGDF8 geneGeneticGenetic TranscriptionGoalsGrantHand StrengthHemodialysisHumanImpairmentIndicanIngestionInternationalKidneyKidney TransplantationKnock-outKynurenic AcidKynurenineLigandsLinkLiteratureManuscriptsMechanicsMembraneMentorsMetabolismMitochondriaModernizationMolecularMolecular BiologyMusMuscleMuscle CellsMuscle FibersMuscle MitochondriaMuscle ProteinsMuscular AtrophyMyopathyPathologyPathway interactionsPatientsPhenocopyPhenotypePhysiologyPlayProductionPropertyProtein BiosynthesisProteinsProteomicsPublishingQuality of lifeReactive Oxygen SpeciesReceptor ActivationRenal functionResearchRespiratory physiologyRodent ModelRoleScientistSkeletal MuscleSymptomsSystemTamoxifenTestingToxic effectToxinTrainingTraining ProgramsTransgenic OrganismsTryptophanUbiquitinUremiaWorkWritingXenobiotic Metabolismaryl hydrocarbon receptor ligandcareerexperimental studyin vivoindoleacetic acidknock-downmitochondrial dysfunctionmulticatalytic endopeptidase complexnovelpre-doctoralpreventpromoterprotective effectprotein degradationprotein metabolitereceptorreceptor bindingsenior facultyskeletalskill acquisitionskillssmall hairpin RNAsolutesymposiumwasting
项目摘要
Abstract
Chronic Kidney Disease (CKD) is accompanied by a progressively debilitating myopathy characterized by
muscle wasting, weakness, and fatigue. Activation of proteolytic pathways including the ubiquitin proteasome
system, caspases/calpains, myostatin, and dysregulation of autophagy have been implicated as causal factors
for muscle wasting and reduced quality of life in patients. Despite this body of literature, the systemic molecular
mechanism(s) linking impaired kidney function to activation of these pathways in muscle remains unknown. A
major function of the kidneys is to rid the body of waste materials that are ingested or produced endogenously
by normal metabolism. However, CKD results in the retention and accumulation of metabolites, termed uremia.
A number of these metabolites are derived from tryptophan catabolism through indolic and kynurenine pathways
including; indoxyl sulfate, L-kynurenine, kynurenic acid, and indole-3-acetic acid which are ligands for the aryl
hydrocarbon receptor (AHR), a transcriptional regulator of xenobiotic metabolism. The AHR usually upregulates
detoxifying pathways such as cytochrome P450 enzymes, however chronic activation of the AHR can be toxic.
My preliminary data reveals robust AHR activation in skeletal muscle of both mice and humans with CKD.
Furthermore, treatment of muscle cells with tryptophan-derived AHR ligands results in mitochondrial dysfunction,
which was prevented by genetic knockdown of the AHR with short hairpin RNA. Lastly, expression of a
constitutively active AHR receptor in muscle cells mimicked uremic metabolite exposure causing atrophy and
mitochondrial dysfunction. Based on these preliminary data, I propose to test my hypothesis that chronic
activation of the AHR plays a causal role in CKD-associated myopathy. Aim 1 will determine if muscle-specific
knockout of the AHR protects against muscle atrophy and mitochondrial dysfunction in mice with CKD using a
Cre-lox system and delivery of tamoxifen to induce muscle specific knockout of the AHR at the onset of CKD.
Aim 2 will test whether constitutive AHR activation via AAV delivery is sufficient to cause muscle atrophy and
mitochondrial dysfunction in mice with normal kidney function. A detailed training program with a mixture of
junior/senior faculty that involves specific research skill enhancement in molecular biology, muscle mechanics,
mitochondrial energetics, and renal physiology has been developed. The application will receive additional
career mentoring involving grant/manuscript writing, presentation skills, and professional development including
participation in national and international scientific conferences. Completion of the aims and training plan will
result in excellent training in mitochondrial functional analysis, muscle biology and contractile function, renal
physiology, protein synthesis and degradation, and proteomics which will provide a strong foundation for my
career goals.
抽象的
慢性肾脏疾病(CKD)伴随着一种逐渐使人衰弱的肌病
肌肉浪费,无力和疲劳。包括泛素蛋白酶体的蛋白水解途径的激活
系统,胱天蛋白酶/钙蛋白酶,肌生抑素和自噬的失调已被视为因果因素
肌肉浪费和患者生活质量降低。尽管文献有很多文献,但全身分子
将受损的肾功能与这些肌肉中这些途径激活联系起来的机制仍然未知。一个
肾脏的主要功能是消除被摄入或内源产生的废物的物体
通过正常代谢。但是,CKD导致代谢物的保留和积累,称为尿毒症。
这些代谢产物中的许多是通过色氨酸分解代谢来源的,
包括;吲哚基硫酸盐,l-京难是,雌二酸和吲哚-3-乙酸,它们是芳基的配体
碳氢化合物受体(AHR),一种异种生物代谢的转录调节剂。 AHR通常上调
排毒途径,例如细胞色素P450酶,但是AHR的慢性激活可能是有毒的。
我的初步数据揭示了使用CKD的小鼠和人类的骨骼肌中强大的AHR激活。
此外,用色氨酸衍生的AHR配体治疗肌肉细胞会导致线粒体功能障碍,
用短发夹RNA遗传AHR的遗传敲低阻止了这种情况。最后,表达
肌肉细胞中的组成性活性AHR受体模仿尿毒症代谢产物,导致萎缩和
线粒体功能障碍。基于这些初步数据,我建议测试我的假设
AHR的激活在与CKD相关的肌病中起因果作用。 AIM 1将确定肌肉特异性是否
AHR的敲除可以使用A的CKD中的小鼠中的肌肉萎缩和线粒体功能障碍
Cre-lox系统和他莫昔芬在CKD发作时诱导AHR的肌肉特异性敲除。
AIM 2将测试通过AAV传递的组成型AHR激活是否足以引起肌肉萎缩和
肾功能正常的小鼠的线粒体功能障碍。详细的培训计划,混合
涉及分子生物学,肌肉力学的特定研究技能的初级/高级教师,
线粒体能量学和肾脏生理学已经开发。该申请将获得额外
职业指导涉及赠款/手稿写作,演示技巧和专业发展,包括
参加国家和国际科学会议。目标和培训计划的完成将
在线粒体功能分析,肌肉生物学和收缩功能,肾脏方面进行了出色的培训
生理,蛋白质合成和降解以及蛋白质组学,这将为我的我
职业目标。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reversible Thiol Oxidation Increases Mitochondrial Electron Transport Complex Enzyme Activity but Not Respiration in Cardiomyocytes from Patients with End-Stage Heart Failure.
- DOI:10.3390/cells11152292
- 发表时间:2022-07-25
- 期刊:
- 影响因子:6
- 作者:
- 通讯作者:
NMR Spectroscopy Identifies Chemicals in Cigarette Smoke Condensate That Impair Skeletal Muscle Mitochondrial Function.
- DOI:10.3390/toxics10030140
- 发表时间:2022-03-14
- 期刊:
- 影响因子:4.6
- 作者:Khattri RB;Thome T;Fitzgerald LF;Wohlgemuth SE;Hepple RT;Ryan TE
- 通讯作者:Ryan TE
Single-Nuclei RNA-Sequencing of the Gastrocnemius Muscle in Peripheral Artery Disease.
- DOI:10.1161/circresaha.123.323161
- 发表时间:2023-10-27
- 期刊:
- 影响因子:20.1
- 作者:Pass, Caroline G.;Palzkill, Victoria;Tan, Jianna;Kim, Kyoungrae;Thome, Trace;Yang, Qingping;Fazzone, Brian;Robinson, Scott T.;O'Malley, Kerri A.;Yue, Feng;Scali, Salvatore T.;Berceli, Scott A.;Ryan, Terence E.
- 通讯作者:Ryan, Terence E.
Mitochondrial Bioenergetic and Proteomic Phenotyping Reveals Organ-Specific Consequences of Chronic Kidney Disease in Mice.
- DOI:10.3390/cells10123282
- 发表时间:2021-11-24
- 期刊:
- 影响因子:6
- 作者:Thome T;Coleman MD;Ryan TE
- 通讯作者:Ryan TE
IGF-1 Therapy Improves Muscle Size and Function in Experimental Peripheral Arterial Disease.
- DOI:10.1016/j.jacbts.2022.12.006
- 发表时间:2023-06
- 期刊:
- 影响因子:9.7
- 作者:Dong, Gengfu;Moparthy, Chatick;Thome, Trace;Kim, Kyoungrae;Yue, Feng;Ryan, Terence E.
- 通讯作者:Ryan, Terence E.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Trace Thome其他文献
Trace Thome的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Trace Thome', 18)}}的其他基金
Chronic aryl hydrocarbon receptor activation and skeletal myopathy in chronic kidney disease
慢性肾病中的慢性芳烃受体激活和骨骼肌病
- 批准号:
10313122 - 财政年份:2021
- 资助金额:
$ 3.79万 - 项目类别:
Chronic aryl hydrocarbon receptor activation and skeletal myopathy in chronic kidney disease
慢性肾病中的慢性芳烃受体激活和骨骼肌病
- 批准号:
10455468 - 财政年份:2021
- 资助金额:
$ 3.79万 - 项目类别:
相似国自然基金
玛纳斯河流域上游吸收性气溶胶来源及其对积雪消融的影响研究
- 批准号:42307523
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向肝癌射频消融的智能建模与快速动力学分析方法研究及其临床验证
- 批准号:62372469
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
IRF9调控CD8+T细胞介导微波消融联合TIGIT单抗协同增效抗肿瘤的作用机制
- 批准号:82373219
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
建立可诱导细胞消融系统揭示成纤维细胞在墨西哥钝口螈肢体发育及再生中的作用
- 批准号:32300701
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肿瘤源PPIA介导结直肠癌肝转移射频消融术残瘤化疗抵抗的机制研究
- 批准号:82302332
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 3.79万 - 项目类别:
A novel, one stop, affordable, point of care and artificial intelligence supported system of screening, triage and treatment selection for cervical cancer and precancer in the LMICs
一种新型、一站式、经济实惠的护理点和人工智能支持系统,用于中低收入国家宫颈癌和癌前病变的筛查、分诊和治疗选择
- 批准号:
10560812 - 财政年份:2023
- 资助金额:
$ 3.79万 - 项目类别:
RepurPosed AntiretrOviraL ThErapieS to EliminAte Cervical Cancer (POLESA Trial)
重新利用抗逆转录病毒疗法来消除宫颈癌(POLESA 试验)
- 批准号:
10738121 - 财政年份:2023
- 资助金额:
$ 3.79万 - 项目类别: